Growth Differentiation Factor 15: A Novel Biomarker for Precision Diagnosis and Treatment of Acute Coronary Syndrome

Author: Senior Product Manager of UA Views：13

This article focuses on the molecular characteristics and clinical application value of growth differentiation factor-15 (GDF-15), systematically elaborating its expression regulation patterns as a member of the transforming growth factor-β superfamily under cardiovascular pathological conditions. It analyzes the clinical significance of GDF-15 in the diagnosis, risk stratification, and prognosis assessment of acute coronary syndrome, and explores the application strategies of its combined detection with traditional myocardial injury biomarkers.

Recent Advances
Product Information

Recent Advances

Growth Differentiation Factor 15: A Novel Biomarker for Precision Diagnosis and Treatment of Acute Coronary Syndrome

Summary: This article systematically elaborates on the molecular characteristics and clinical application value of Growth Differentiation Factor 15 (GDF-15), a member of the transforming growth factor-β superfamily, focusing on its expression regulation patterns under cardiovascular pathological conditions. It analyzes the clinical significance of GDF-15 in the diagnosis, risk stratification, and prognosis assessment of acute coronary syndrome, and explores the application strategies of its combined detection with traditional myocardial injury markers.

1. Clinical Challenges in Cardiovascular Diseases and the Need for Novel Biomarkers

Cardiovascular diseases are one of the leading causes of human mortality and shortened healthy life expectancy. The prevalence of cardiovascular diseases in China continues to rise, with an estimated 330 million people currently affected. Acute coronary syndrome refers to a cardiac acute ischemic syndrome caused by the rupture or erosion of unstable atherosclerotic plaques in the coronary arteries, leading to fresh thrombus formation. It often presents with chest pain and can be fatal within hours or days. Early diagnosis is crucial for timely relief of myocardial injury, guiding optimal drug therapy and revascularization, and early intervention can help reduce the occurrence of severe complications.

Cardiac biomarkers play a vital role in the diagnosis, treatment, and prognosis assessment of acute coronary syndrome. B-type natriuretic peptide, D-dimer, cardiac troponin, creatine kinase isoenzyme, and myoglobin are currently the most common primary detection indicators. However, as research progresses, the limitations of existing detection methods have become increasingly apparent, making the study of novel molecular markers for acute coronary syndrome a hot topic among clinicians and researchers. In this context, Growth Differentiation Factor 15 has garnered widespread attention due to its unique expression regulation characteristics and clinical predictive value.

2. Molecular Characteristics and Expression Regulation of GDF-15

Growth Differentiation Factor 15, also known as macrophage inhibitory cytokine-1, is a member of the transforming growth factor-β superfamily. Structurally, GDF-15 is a secreted homodimeric protein whose biological activity depends on the C-terminal mature peptide. Under physiological conditions, GDF-15 is highly expressed only in placental tissue and minimally expressed in organs such as the pancreas, liver, and kidneys. Under pathological conditions, such as inflammation, ischemia, hypoxia, or organ damage, GDF-15 expression levels increase. Although GDF-15 is not expressed in the heart under normal conditions, its levels can rapidly rise in cardiovascular injuries such as coronary artery disease, pressure overload, and ischemia-reperfusion. This "silent at rest, explosive upon injury" expression characteristic makes it a highly promising biomarker for cardiovascular injury.

3. Clinical Predictive Value of GDF-15 in Acute Coronary Syndrome

In October 2022, the Emergency Medicine Committee of the Chinese Medical Doctor Association released the "Expert Consensus on the Clinical Application of Growth Differentiation Factor-15 in Acute Coronary Syndrome in Emergency Settings," providing authoritative recommendations on a series of issues related to the emergency application of GDF-15. Serum GDF-15 levels can predict adverse outcomes in acute coronary syndrome, with high levels indicating an increased risk of recurrent spontaneous myocardial infarction and stroke. Serum GDF-15 levels are also an indicator for predicting one-year mortality in patients with non-ST-segment elevation myocardial infarction, where higher concentrations of GDF-15 are associated with a greater risk of death and recurrent myocardial infarction.

The diagnosis of heart failure is primarily based on a comprehensive evaluation of medical history, clinical manifestations, echocardiography, chest X-rays, and other tests. GDF-15 levels, when combined with clinical judgment and other parameters, can further enhance the ability to predict heart failure in patients with acute coronary syndrome. This finding suggests that GDF-15 not only serves as an independent prognostic marker but also as a valuable supplement to traditional clinical assessment systems.

4. Reference Range and Detection Strategies for GDF-15

The normal concentration range for GDF-15 used in foreign literature is less than 1200 ng/L, a conclusion derived from the analysis of serum GDF-15 levels in 429 healthy individuals with an average age of 65. Subsequent studies in patients with non-ST-segment elevation acute coronary syndrome found that approximately two-thirds of patients had serum GDF-15 levels above the upper limit of 1200 ng/L.

In emergency clinical applications, for all patients presenting with acute chest pain and associated risk factors, rapid combined testing of GDF-15 and traditional cardiovascular biomarkers is recommended. Different test results will guide the corresponding diagnostic pathways. This combined detection strategy can improve early identification of acute coronary syndrome, providing a critical time window for timely intervention.

5. Expanded Applications of GDF-15 in Cardiovascular Diseases

Beyond the expert consensus highlighting the enhanced diagnostic capability of GDF-15 when combined with traditional myocardial injury markers, studies have also found that GDF-15 levels have clinical value in assessing the severity of cardiovascular diseases, predicting the prognosis and risk stratification of chronic heart failure, and evaluating bleeding risks in atrial fibrillation patients undergoing anticoagulant therapy. In chronic heart failure, GDF-15 levels are significantly correlated with functional class and prognosis, serving as an auxiliary indicator for risk stratification. In atrial fibrillation patients, GDF-15 levels are associated with bleeding risks post-anticoagulation therapy, aiding in the development of personalized anticoagulation regimens. These expanded applications demonstrate the broad potential of GDF-15 in the comprehensive management of cardiovascular diseases.

6. Conclusion

In basic research and clinical translation related to GDF-15, high-quality recombinant GDF-15 protein is a core tool for elucidating its cardiovascular protective mechanisms and evaluating the performance of detection methods. To meet this research need, Uni offers GDF-15/MIC-1 Protein, Mouse. This product is suitable for studying GDF-15 expression in mouse cardiovascular disease models, establishing and validating GDF-15 immunoassay methods, and exploring the mechanisms of GDF-15 in myocardial ischemia and heart failure, among other applications.

As an important member of the transforming growth factor-β superfamily, Growth Differentiation Factor 15 has emerged as a novel biomarker of great interest in the field of cardiovascular diseases due to its rapid induction under pathological conditions, independent association with adverse outcomes in acute coronary syndrome, and supplementary value in assessing heart failure and atrial fibrillation risks. Its combined detection strategy with traditional myocardial injury markers provides new technical means for the early diagnosis and precision management of acute coronary syndrome. GDF-15/MIC-1 Protein, Mouse offers reliable tool support for GDF-15-related mechanism research and detection method development, driving further exploration in the field of precision diagnosis and treatment of cardiovascular diseases.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next